2007
DOI: 10.1056/nejmoa066596
|View full text |Cite
|
Sign up to set email alerts
|

Survival after Treatment with Phenylacetate and Benzoate for Urea-Cycle Disorders

Abstract: Prompt recognition of a urea-cycle disorder and treatment with both sodium phenylacetate and sodium benzoate, in conjunction with other therapies, such as intravenous arginine hydrochloride and the provision of adequate calories to prevent catabolism, effectively lower plasma ammonium levels and result in survival in the majority of patients. Hemodialysis may also be needed to control hyperammonemia, especially in neonates and older patients who do not have a response to intravenous sodium phenylacetate and so… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

14
246
0
6

Year Published

2008
2008
2019
2019

Publication Types

Select...
3
3
2

Relationship

1
7

Authors

Journals

citations
Cited by 309 publications
(266 citation statements)
references
References 26 publications
14
246
0
6
Order By: Relevance
“…Lactic acidosis at admission is unusual in OTCD crises but may be explained in the present case by either an initial vasomotor instability related to brain edema or by transient ischemic brain damage, in accordance with the severity of this episode. The presence of a coma at admission was reported to be associated with a lower survival rate, particularly in OTCD patients (Enns et al 2007), and neurological symptoms persisted even after decreasing ammonemia levels under 100 mmol/L. In UCD, the function of excretion of nitrogen as urea is impaired and leads to accumulate ammonia and glutamine, two toxic molecules for the brain.…”
Section: Discussionmentioning
confidence: 99%
“…Lactic acidosis at admission is unusual in OTCD crises but may be explained in the present case by either an initial vasomotor instability related to brain edema or by transient ischemic brain damage, in accordance with the severity of this episode. The presence of a coma at admission was reported to be associated with a lower survival rate, particularly in OTCD patients (Enns et al 2007), and neurological symptoms persisted even after decreasing ammonemia levels under 100 mmol/L. In UCD, the function of excretion of nitrogen as urea is impaired and leads to accumulate ammonia and glutamine, two toxic molecules for the brain.…”
Section: Discussionmentioning
confidence: 99%
“…Patient-specific factors -when comparing pediatric patients with IEM with adults, it may be reasonable to assume that those patients who survive to adulthood have less severe disease and therefore are less likely to require a transplant for survival. While it is true that the survival rate of patients presenting over the age of 12 years with conditions like urea cycle defects and symptomatic hyperammonemia is much higher than those with earlier onset presentations (Enns et al 2007), mortality rate is high in patients with severe symptoms of an IEM regardless of age. For example, 25 % of female OTC patients who present with coma (Enns et al 2007) and 29 % of adults with acute presentations of MCAD (Lang 2009) will die.…”
Section: Discussionmentioning
confidence: 99%
“…While it is true that the survival rate of patients presenting over the age of 12 years with conditions like urea cycle defects and symptomatic hyperammonemia is much higher than those with earlier onset presentations (Enns et al 2007), mortality rate is high in patients with severe symptoms of an IEM regardless of age. For example, 25 % of female OTC patients who present with coma (Enns et al 2007) and 29 % of adults with acute presentations of MCAD (Lang 2009) will die. These publications (Enns et al 2007, Lang 2009) reflect a publication bias in that they focus on symptomatic cases and many adult patients with IEM such as MCAD will be asymptomatic.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Algunos de ellos han sido empleados con éxito en pacientes con trastornos del ciclo de la urea (55), otros se han desarrollado específicamente para el tratamiento de la EH en pacientes con cirrosis hepática (56).…”
Section: Moduladores Del Metabolismo Del Amoniacounclassified